ImmunovantIMVT
IMVT
About: Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
Employees: 362
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
105% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 44
29% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 28
17% more call options, than puts
Call options by funds: $34.5M | Put options by funds: $29.5M
3% more funds holding
Funds holding: 186 [Q4 2024] → 192 (+6) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
0.65% less ownership
Funds ownership: 56.06% [Q4 2024] → 55.41% (-0.65%) [Q1 2025]
21% less capital invested
Capital invested by funds: $2.04B [Q4 2024] → $1.61B (-$429M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$18
8%
upside
Avg. target
$18
8%
upside
High target
$18
8%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
UBS Ashwani Verma | 8%upside $18 | Neutral Maintained | 28 Jul 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
2 months ago
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant stock rises on encouraging fourth-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
Neutral
GlobeNewsWire
2 months ago
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD) and a potentially registrational study in Sjögren's disease (SjD), both expected to start in summer 2025 Positive data from first-generation batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) demonstrated that deeper IgG reductions correlated with improved clinical outcomes across a range of assessments and timepoints suggesting a potential best-in-class efficacy profile for IMVT-1402 Current cash balance provides runway for announced indications through GD readout expected in 2027 NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2025. Recent Highlights and Upcoming Milestones: In April 2025, Immunovant announced changes to its leadership team as part of a broader strategic transition with Roivant increasing operational involvement and oversight of Immunovant.
Neutral
Business Wire
2 months ago
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. – Immunovant's controlling stockholder – in connection with Immunovant's January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day's closing.
Negative
Investors Business Daily
3 months ago
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.
Positive
Zacks Investment Research
4 months ago
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Positive
Seeking Alpha
4 months ago
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoclimab in phase 2b study targeting patients with Chronic Inflammatory Demyelinating Polyneuropathy; IgG was reduced by ≥ 70%. Data from both phase 3 studies, using batoclimab to treat patients with Active Thyroid Eye Disease, expected 2nd half of 2025.
Neutral
PRNewsWire
4 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
NEW YORK , March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant's directors breached their fiduciary duties in connection with recent corporate actions.
Charts implemented using Lightweight Charts™